

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
The Approval of LuX-Valve Plus
by the Hong Kong Department of Health

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The Board (the “**Board**”) of Directors (the “**Director(s)**”) of the Company is pleased to announce that LuX-Valve Plus, the Company’s transvenous tricuspid valve replacement system, has recently received approval from the Department of Health of the Hong Kong Special Administrative Region of the People’s Republic of China (the “**Hong Kong Department of Health**”), and the Company is actively pursuing the commercialization of this product in Hong Kong, China.

LuX-Valve Plus is the world’s second approved transvenous orthotopic tricuspid valve replacement system. Leveraging the product’s unique advantages, ongoing efforts to promote the therapy and extensive clinical experience, LuX-Valve Plus has gained widespread recognition in the market. LuX-Valve Plus has now received regulatory approval in numerous countries and regions across Europe, the Middle East and the Asia-Pacific. This approval of LuX-Valve Plus by the Hong Kong Department of Health further validates the product’s potential in the treatment of tricuspid regurgitation. The Company will continue to accelerate the global commercialization of LuX-Valve Plus to further advance our long-term strategic objectives.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 4 September 2026

As at the date of this announcement, the executive Director of the Company is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.